Chargement en cours...

A Randomized, Double-blind, Placebo-controlled Trial of the Efficacy and Safety of Levomilnacipran ER 40-120mg/day for Prevention of Relapse in Patients with Major Depressive Disorder

Objective: Major depressive disorder is often chronic, with relapse and recurrence common. Levomilnacipran extended-release is a potent and selective serotonin and reuptake inhibitor approved in the United States for treatment of major depressive disorder in adults. The objective of this study (NCT0...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Shiovitz, Thomas, Greenberg, William M., Chen, Changzheng, Forero, Giovanna, Gommoll, Carl P.
Format: Artigo
Langue:Inglês
Publié: Matrix Medical Communications 2014
Sujets:
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC3960779/
https://ncbi.nlm.nih.gov/pubmed/24653937
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!